Your email has been successfully added to our mailing list.

×
-0.00468305736745277 -0.00468305736745277 -0.000836260244188062 -0.00278474661314612 -0.0045158053186152 0.00602107375815353 -0.00635557785582878 -0.00242515470814523
Stock impact report

The first KRAS drugs have been sluggish on the market. Will the next generation fare better? [Yahoo! Finance]

Bristol-Myers Squibb Company (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
Company Research Source: Yahoo! Finance
This story was originally published on PharmaVoice . To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter When the FDA granted Amgen's KRAS drug Lumakras accelerated approval in 2021, it marked a milestone moment for a target once deemed undruggable. For decades, scientists knew that mutations of the KRAS gene accelerated several deadly types of cancer, but the resulting protein's smooth surface repelled all the drugs they threw at it. Amgen scientists identified and exploited a critical weakness: small, previously unrecognized pockets that allowed Lumakras to bind to the protein and flip the off switch, according to I-Fen Chang, vice president of oncology global development at Amgen, in an email. Despite the excitement surrounding its launch, Lumakras has seen modest commercial success, largely due to a limited patient population and reimbursement challenges, especially in markets outside the U.S., said Neha Anand, an analyst at Citeline. Th Show less Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for BMY alerts
Opt-in for
BMY alerts

from News Quantified
Opt-in for
BMY alerts

from News Quantified